TNSN98158A1 - Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation - Google Patents

Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation

Info

Publication number
TNSN98158A1
TNSN98158A1 TNTNSN98158A TNSN98158A TNSN98158A1 TN SN98158 A1 TNSN98158 A1 TN SN98158A1 TN TNSN98158 A TNTNSN98158 A TN TNSN98158A TN SN98158 A TNSN98158 A TN SN98158A TN SN98158 A1 TNSN98158 A1 TN SN98158A1
Authority
TN
Tunisia
Prior art keywords
amlodipine
preparation
statin
pharmaceutical combinations
treatment
Prior art date
Application number
TNTNSN98158A
Other languages
English (en)
Inventor
Buch Jan
Andrew Donald Scott Robert
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22011309&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TNSN98158(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TNSN98158A1 publication Critical patent/TNSN98158A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)

Abstract

L'INVENTION CONCERNE DES ASSOCIATIONS PHARMACEUTIQUES D'AMLODIPINE OU D'UN DES SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES ET D'UNE STATINE OU DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES. ELLE CONCERNE EGALEMENT UN PROCEDE POUR LA PREPARATION D'ASSOCIATIONS DE COMPOSITIONS PHARMACEUTIQUES AINSI QUE DES KITS CONTENANT CELLES-CI. APPLICATION : UTILISATION POUR LE TRAITEMENT DE SUJETS SOUFFRANT D'ANGINE DE POITRINE, D'ATHEROSCLEROSE, D'HYPERTENSION ET D'HYPERLIPIDEMIE EN ASSOCIATION, ET POUR LE TRAITEMENT DE SUJETS PRESENTANT DES SYMPTOMES DE RISQUES CARDIAQUES.
TNTNSN98158A 1997-08-29 1998-08-26 Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation TNSN98158A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5755597P 1997-08-29 1997-08-29

Publications (1)

Publication Number Publication Date
TNSN98158A1 true TNSN98158A1 (fr) 2005-03-15

Family

ID=22011309

Family Applications (1)

Application Number Title Priority Date Filing Date
TNTNSN98158A TNSN98158A1 (fr) 1997-08-29 1998-08-26 Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation

Country Status (37)

Country Link
US (1) US20020025981A1 (fr)
EP (1) EP1003507A1 (fr)
JP (1) JP2001514224A (fr)
KR (1) KR20010022385A (fr)
CN (1) CN1117566C (fr)
AP (1) AP1207A (fr)
AR (1) AR017514A1 (fr)
AU (1) AU744982B2 (fr)
BG (1) BG104076A (fr)
BR (1) BR9811558A (fr)
CA (1) CA2296726C (fr)
CO (1) CO4970726A1 (fr)
DZ (1) DZ2600A1 (fr)
EA (1) EA002705B1 (fr)
GT (1) GT199800134A (fr)
HK (1) HK1029530A1 (fr)
HN (1) HN1998000124A (fr)
HR (1) HRP980475A2 (fr)
HU (1) HUP0003103A3 (fr)
ID (1) ID24275A (fr)
IL (2) IL133957A0 (fr)
IS (1) IS5345A (fr)
MA (1) MA26539A1 (fr)
NO (1) NO20000999D0 (fr)
NZ (1) NZ502283A (fr)
OA (1) OA11289A (fr)
PA (1) PA8457201A1 (fr)
PE (1) PE106999A1 (fr)
PL (1) PL339088A1 (fr)
SA (1) SA98190432A (fr)
SK (1) SK1392000A3 (fr)
TN (1) TNSN98158A1 (fr)
TR (1) TR200000562T2 (fr)
UY (1) UY25159A1 (fr)
WO (1) WO1999011263A1 (fr)
YU (1) YU2700A (fr)
ZA (1) ZA987843B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1076091A1 (fr) * 1999-08-09 2001-02-14 Universite Catholique De Louvain Composé ou composition pharmaceutique pour la prévention et/ou le traitement d'ischémie cardiaque, de maladies vasculaires périphériques, de tumeurs et de plaies
DE19944803A1 (de) * 1999-09-20 2001-03-29 Bayer Ag Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln
EP1314425A4 (fr) * 2000-08-30 2004-06-02 Sankyo Co Compositions medicinales utilisees dans la prevention ou le traitement de l'insuffisance cardiaque
AUPR255401A0 (en) * 2001-01-16 2001-02-08 Novogen Research Pty Ltd Regulation of lipids and/or bone density and compositions therefor
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
NL1019882C2 (nl) * 2002-02-01 2003-08-04 Synthon Licensing Amlodipine vrije base.
US20040053842A1 (en) * 2002-07-02 2004-03-18 Pfizer Inc. Methods of treatment with CETP inhibitors and antihypertensive agents
US7071210B2 (en) * 2002-07-02 2006-07-04 Pfizer Inc. CETP inhibitors in combination with antihypertensive agents and uses thereof
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2005097191A2 (fr) * 2004-04-04 2005-10-20 Sepracor Inc. Combinaisons comprenant de la (s)-amlodipine et un inhibiteur de la hmg-coa reductase ou un inhibiteur de l'absorption de cholesterol ou les deux a la fois et methodes permettant de reduire l'hypertension
KR100582347B1 (ko) * 2004-12-30 2006-05-22 한미약품 주식회사 3-하이드록시-3-메틸글루타릴 조효소 ａ 환원효소 억제제및 고혈압 치료제의 복합제제 및 그의 제조방법
KR100742432B1 (ko) 2005-12-27 2007-07-24 한미약품 주식회사 암로디핀 캠실레이트 및 심바스타틴을 포함하는 복합제제,및 이의 제조방법
CA2645281A1 (fr) 2006-03-29 2007-10-04 Kowa Co., Ltd. Agent favorisant la baisse des triglycerides et agent ameliorant l'hyperinsulinisme
WO2008023958A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. Composition pharmaceutique combinée à libération contrôlée comprenant de la dihydropyridine, des bloqueurs de canal calcium et des inhibiteurs de l'hgm-coa réductase
WO2008023869A1 (fr) * 2006-08-24 2008-02-28 Hanall Pharmaceutical Co., Ltd. PRÉPARATION PHARMACEUTIQUE COMBINÉE À LIBÉRATION CONTRÔLÉE COMPRENANT DES INHIBITEURS CALCIQUES À BASE DE DIHYDROPYRIDINE ET DES INHIBITEURS DE HMG-CoA RÉDUCTASE
MX2007008440A (es) * 2007-07-11 2009-02-18 Senosiain S A De C V Lab Composicion farmaceutica combinada.
KR20090091084A (ko) * 2008-02-22 2009-08-26 한올제약주식회사 방출성이 제어된 약제학적 제제
WO2009125987A2 (fr) * 2008-04-10 2009-10-15 한올제약주식회사 Préparation pharmaceutique
WO2010008203A2 (fr) * 2008-07-15 2010-01-21 한올제약주식회사 Preparation pharmaceutique contenant un inhibiteur des canaux calciques
CN101804055B (zh) * 2010-04-27 2012-01-25 施慧达药业集团(吉林)有限公司 复方药物制剂
AR103624A1 (es) * 2015-02-06 2017-05-24 Intercept Pharmaceuticals Inc Composiciones farmacéuticas para terapia de combinación
EP3706799A4 (fr) * 2017-11-10 2021-08-25 Op-T Llc Procédés de prévention, de modulation et/ou de réduction d'une maladie cardiovasculaire
US11793854B2 (en) 2019-03-21 2023-10-24 Op-T Llc Methods for reducing symptoms of multiple sclerosis using a six-amino acid long peptide that inhibits CD40-CD150 interaction
CN114727955B (zh) * 2019-11-25 2024-03-26 福多兹制药公司 包含降脂和降血压药物的制剂
CN112826937B (zh) * 2021-03-25 2022-03-22 山东大学齐鲁医院 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN176897B (fr) * 1993-10-29 1996-09-28 Cadila Lab Ltd
DE19539363A1 (de) * 1995-10-23 1997-04-24 Basf Ag Verfahren zur Herstellung von festen Arzneiformen

Also Published As

Publication number Publication date
EA200000013A1 (ru) 2000-08-28
IL133957A (en) 2006-06-11
BR9811558A (pt) 2000-08-22
NO20000999L (no) 2000-02-28
TR200000562T2 (tr) 2000-08-21
PL339088A1 (en) 2000-12-04
MA26539A1 (fr) 2004-12-20
HK1029530A1 (en) 2001-04-06
KR20010022385A (ko) 2001-03-15
IL133957A0 (en) 2001-04-30
AU744982B2 (en) 2002-03-07
AU8458598A (en) 1999-03-22
CA2296726C (fr) 2004-06-29
HUP0003103A2 (hu) 2001-01-29
OA11289A (en) 2003-08-25
PE106999A1 (es) 1999-11-06
EA002705B1 (ru) 2002-08-29
AP9801333A0 (en) 1998-09-30
YU2700A (sh) 2002-06-19
SK1392000A3 (en) 2000-08-14
IS5345A (is) 2000-01-14
PA8457201A1 (es) 2000-05-24
US20020025981A1 (en) 2002-02-28
CN1117566C (zh) 2003-08-13
AP1207A (en) 2003-09-20
EP1003507A1 (fr) 2000-05-31
HRP980475A2 (en) 1999-06-30
GT199800134A (es) 2000-02-08
BG104076A (en) 2000-09-29
CA2296726A1 (fr) 1999-03-11
NO20000999D0 (no) 2000-02-28
AR017514A1 (es) 2001-09-12
HN1998000124A (es) 1999-02-09
WO1999011263A1 (fr) 1999-03-11
CO4970726A1 (es) 2000-11-07
SA98190432A (ar) 2005-12-03
ID24275A (id) 2000-07-13
NZ502283A (en) 2002-05-31
JP2001514224A (ja) 2001-09-11
CN1268054A (zh) 2000-09-27
HUP0003103A3 (en) 2002-03-28
UY25159A1 (es) 2000-12-29
DZ2600A1 (fr) 2003-03-01
ZA987843B (en) 2000-02-28

Similar Documents

Publication Publication Date Title
TNSN98158A1 (fr) Associations pharmaceutiques d'amlodipine et d'une statine, et procede pour leur preparation
TNSN98156A1 (fr) Associations pharmaceutiques d'amlodipine et d'atorvastatine et procede pour leur preparation
TNSN98155A1 (fr) Associations de compositions pharmaceutiques d'atorvastatine et d'agents antihypertensifs, et procede pour leur preparation
TNSN00110A1 (fr) Sel mutuel d'amlodipine et d'atorvastatine, procede pour sa preparation et compositions pharmaceutiques le contenant
TNSN01125A1 (fr) Compositions pharmaceutiques comprenant un inhibiteur de cetp et de l'atorvastatine
TNSN98017A1 (fr) Derives de sulfonyluree, procede pour leur preparation et compositions pharmaceutiques les contenant.
CA2191129A1 (fr) Medicaments a base de metronidazole ou d'un melange synergetique de metronidazole et de clindamycine
TNSN99053A1 (fr) Hydroxamides d'acides (4-arylsulfonylamino)-tetrahydro- pyranne-4-carboxyliques), procede pour leur preparation et compositions les contenant
TNSN97193A1 (fr) Amides inhibiteurs de secretion de apo b/mtp, procede pour leur preparation et compositions pharmaceutiques les contenant.
TNSN98025A1 (fr) Derives d'acide arylsulfonylhydroxamique, procede pour leur preparation et compositions les contenant.
TNSN99172A1 (fr) 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN99006A1 (fr) 4-(2-ceto-1-benzimidazolinyl) piperidines nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN04022A1 (fr) Compositions pharmaceutiques d'amlodipine et d'atorvastatine
TNSN99110A1 (fr) Inhibiteurs non peptidiques de l'adhesion cellulaire sous la dependance de vla-4, procede pour leur preparation et compositions pharmaceutiques les contenant
TNSN96153A1 (fr) Procedes et intermediaires pour la preparation de 1-benzyl-4 ((5,6 -dimethoxy-1-indanone)-2- yl) methylpiperidine.
TNSN99013A1 (fr) Derives d'acide dihydroxyhexanoique nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant
MA24704A1 (fr) Formulations nouvelles de paroxetine et procede pour leur preparation
TNSN00142A1 (fr) Complexe d'eletriptan et d'une sulfobutylether- betacyclodextrine, procede pour sa preparation et compositions pharmaceutiques les contenant.
TNSN99199A1 (fr) FORMULATIONS PHARMACEUTIQUES D'INHIBITEURS DE PDE-5 DE GMPc A LIBERATION CONTROLEE, ET PROCEDE POUR LEUR PREPARATION